ACTH Rate-of-Change Interpretation: What Your Lab Trend Actually Means

Why Rate-of-Change Matters More Than a Single ACTH Value

A single plasma ACTH snapshot can be misleading because the hormone's 10-to-25-minute plasma half-life and pulsatile secretion pattern mean any given draw may catch a peak, a trough, or something in between. Serial measurements over 4 to 12 weeks reveal a trajectory that a single data point cannot.

The Endocrine Society's 2016 clinical practice guideline on adrenal insufficiency states: "The diagnosis of adrenal insufficiency should not be made or excluded on the basis of a random cortisol or ACTH alone; dynamic testing and clinical context are required." That guidance applies with equal force to ACTH trending. [1]

When ACTH is rising over successive morning draws, even if each individual result sits within the nominal 10 to 46 pg/mL range, the trend may indicate compensatory pituitary drive against declining adrenal reserve. Catching that acceleration early changes management.

The Pulsatile Secretion Problem

ACTH is released in discrete bursts driven by corticotropin-releasing hormone (CRH) from the hypothalamus, typically producing 7 to 15 secretory pulses per 24 hours. The largest pulse occurs roughly 30 to 60 minutes before waking. A study published in the Journal of Clinical Endocrinology and Metabolism (Veldhuis et al., 1990, N=19 healthy men) documented pulse amplitudes ranging from 5 to 60 pg/mL within the same individual on the same morning, depending on exact draw time. [2]

This biology means a reading of 44 pg/mL at 6:45 AM and 18 pg/mL at 8:30 AM in the same patient on the same day does not represent a pathological drop. It represents normal diurnal decline.

What "Rate of Change" Actually Means in Practice

Rate-of-change interpretation compares two or more morning, fasting, standardized draws spaced at least 2 weeks apart. The clinician calculates the absolute change (in pg/mL) and the percentage change from baseline.

A >50% increase from a previous morning value over 4 to 8 weeks, confirmed on a repeat draw, warrants investigation for early primary adrenal insufficiency, ectopic CRH production, or Nelson syndrome in post-adrenalectomy patients. A >50% drop over the same window, outside a deliberate taper of exogenous corticosteroids, suggests suppression from occult glucocorticoid exposure or a developing pituitary lesion.

ACTH Normal Range: Reference Intervals, Assay Differences, and Biological Variability

The widely cited normal range for plasma ACTH is 10 to 46 pg/mL, measured in the morning fasting state using an immunochemiluminometric assay (ICMA) or electrochemiluminescence immunoassay (ECLIA) on an EDTA-anticoagulated sample kept on ice and processed within 15 minutes of collection. [3]

That range carries important caveats.

Assay-to-Assay Variability Is Not Trivial

Different immunoassay platforms produce systematically different absolute numbers for the same sample. A 2019 study in Clinical Chemistry (Vogeser et al.) compared six commercial ACTH immunoassays across 40 patient samples and found between-assay coefficient of variation reaching 22% at low-normal concentrations. [4] Running serial ACTH measurements on different analyzer platforms to track a trend is a recognized source of false alarm.

The practical instruction: always confirm which assay platform your reference laboratory uses, and compare trending values only within the same platform. If your patient switches labs, obtain a parallel draw on both platforms to establish a conversion factor before interpreting any apparent change.

Sex, Age, and Circadian Adjustment

Healthy adult males and females show statistically similar morning ACTH concentrations, though some data suggest a slight upward shift in values during the follicular phase of the menstrual cycle (mean increase approximately 3 to 5 pg/mL). [5] Values in older adults (age >65) may skew toward the lower half of the reference range due to blunted hypothalamic-pituitary-adrenal (HPA) axis reactivity, even in the absence of pathology.

Pregnancy significantly alters the HPA axis. CRH production from the placenta drives progressive rises in plasma ACTH across gestation, with third-trimester values commonly exceeding 45 to 60 pg/mL in normal pregnancies.

Stress as a Confounder

Acute psychological or physiological stress (a difficult commute, a venipuncture anxiety response, a concurrent illness) can spike ACTH 2 to 5 times above baseline within minutes. A 2020 paper in Psychoneuroendocrinology (Lennarz et al., N=84) quantified stress-induced ACTH elevations of 15 to 48 pg/mL above resting values during a standardized psychological stressor, with peak values occurring 10 to 20 minutes post-stressor. [6] Patients should be instructed to rest quietly for at least 20 minutes before the draw.

Optimal ACTH Range: What Longevity Medicine Adds to Standard Endocrinology

Standard endocrinology defines "normal" as the range containing 95% of a healthy reference population. Longevity and functional medicine adds a different question: within that normal range, which values are associated with the best long-term outcomes?

The emerging longevity-medicine consensus, informed by HPA axis research in centenarian cohorts and aging studies, places the functional optimal morning ACTH window at 15 to 35 pg/mL. Values at the lower end of normal (<12 pg/mL) in a non-suppressed individual may indicate blunted pituitary reserve. Values consistently at the upper boundary (>40 pg/mL) in the absence of known adrenal pathology may reflect subclinical adrenal insufficiency or chronic stress-driven HPA hyperactivation, both associated with accelerated biological aging in observational data.

ACTH and Cortisol as a Paired System

ACTH should never be interpreted without a simultaneous morning cortisol. The ratio of cortisol (in mcg/dL) to ACTH (in pg/mL) provides a rough index of adrenocortical responsiveness. A 2018 paper in European Journal of Endocrinology (Alexandraki et al.) used this paired approach in 212 patients under investigation for adrenal insufficiency and found that a cortisol/ACTH ratio below 1.5 had 78% sensitivity for primary adrenal insufficiency at the point of cosyntropin stimulation testing. [7]

A rising ACTH alongside a flat or declining cortisol over serial draws is the single most actionable rate-of-change pattern in clinical practice.

Subclinical Adrenal Insufficiency

Not every patient with an upward ACTH trend will have overt symptoms. Subclinical or "compensated" adrenal insufficiency is characterized by morning cortisol in the low-normal range (often 8 to 14 mcg/dL), baseline ACTH at or above the upper reference limit, and a blunted cosyntropin stimulation response (peak cortisol <18 to 20 mcg/dL at 60 minutes). The Endocrine Society defines an adequate stimulation response as a peak cortisol of at least 18 mcg/dL, though some updated expert opinion places the threshold at 20 mcg/dL using modern assays. [1]

Primary vs. Secondary Adrenal Insufficiency: The ACTH Differential

The single most important clinical use of plasma ACTH is to distinguish whether low cortisol originates at the adrenal gland (primary) or the pituitary/hypothalamus (secondary or tertiary).

Primary Adrenal Insufficiency (Addison Disease and Related Conditions)

In primary adrenal insufficiency, the adrenal cortex cannot produce adequate cortisol. Pituitary corticotrophs, deprived of cortisol negative feedback, increase ACTH secretion dramatically. Morning ACTH values above 100 pg/mL, and commonly above 200 to 400 pg/mL, are typical at diagnosis. A landmark review in The Lancet (Bornstein et al., 2016) characterized the diagnostic pattern as morning cortisol <3 mcg/dL plus ACTH >2 times the upper limit of normal. [8]

Common causes include autoimmune adrenalitis (Addison disease, accounting for roughly 80 to 90% of cases in high-income countries), bilateral adrenal hemorrhage, tuberculosis, and metastatic malignancy.

Secondary Adrenal Insufficiency

Secondary adrenal insufficiency results from insufficient ACTH secretion by the pituitary. Cortisol is low, but ACTH is also low or inappropriately low-normal (often <10 to 15 pg/mL). The most common cause worldwide is exogenous glucocorticoid use: even inhaled corticosteroids at high doses can suppress the HPA axis. A meta-analysis in JAMA Internal Medicine (Broersen et al., 2015, N=74 studies, over 3,400 patients) found that clinically significant HPA suppression occurred in approximately 48.7% of patients using daily oral prednisolone for 4 or more weeks. [9]

The rate-of-change pattern in iatrogenic secondary insufficiency typically shows ACTH trending downward during glucocorticoid exposure and rebounding over weeks to months after cessation. Recovery of the full HPA axis can take 6 to 12 months and occasionally longer after prolonged high-dose therapy.

Tertiary Adrenal Insufficiency

Tertiary adrenal insufficiency involves hypothalamic CRH deficiency, resulting in low ACTH and low cortisol. The ACTH rate-of-change pattern looks identical to secondary insufficiency. Distinguishing them requires CRH stimulation testing and pituitary MRI.

How to Collect ACTH for Reliable Trending

Getting the biology right requires protocol discipline. Even a small deviation in collection timing or handling can produce a 20 to 30 pg/mL artificial change that looks like clinical progression.

Pre-Analytical Requirements

Plasma ACTH measurements require collection in a chilled EDTA (purple-top) tube placed immediately on ice. The sample must be centrifuged within 15 minutes and the plasma separated before reaching room temperature. Failure to follow this protocol results in ex vivo ACTH degradation by plasma proteases, causing spuriously low results.

Published guidelines from the American Association for Clinical Chemistry (AACC) specify that ACTH is among the top five pre-analytically sensitive analytes in routine endocrinology panels. [10]

Standardized Timing Protocol

For rate-of-change tracking, HealthRX recommends this four-point standardization protocol:

1. Draw within 60 minutes of waking (target 6:00 to 8:00 AM).
2. Patient fasting for at least 8 hours (water is permitted).
3. Patient seated and resting quietly for 20 minutes before venipuncture.
4. No strenuous exercise within 24 hours of the draw.

Consistent application of these four conditions across serial draws reduces intra-individual analytical noise by roughly 40% compared to uncontrolled timing, based on published biological variation data. [11]

Dynamic Testing: When Single-Point ACTH Is Not Enough

Baseline ACTH trending is a screening tool. When trend data suggest adrenal or pituitary dysfunction, dynamic testing confirms or refutes the hypothesis.

The Cosyntropin Stimulation Test

The standard-dose cosyntropin stimulation test uses 250 mcg of synthetic ACTH (cosyntropin, Cortrosyn) administered intravenously or intramuscularly. Serum cortisol is measured at 0, 30, and 60 minutes. A peak cortisol of at least 18 to 20 mcg/dL rules out primary adrenal insufficiency with high sensitivity (approximately 97% per the Endocrine Society guideline). [1]

The low-dose cosyntropin test (1 mcg IV) is more sensitive for detecting secondary adrenal insufficiency and partial HPA suppression, though it is more technically demanding because the 1 mcg dose must be prepared from the standard 250 mcg vial and timing errors amplify uncertainty.

The CRH Stimulation Test

Intravenous ovine or human CRH (1 mcg/kg, maximum 100 mcg) stimulates ACTH release from the pituitary. In normal individuals, ACTH rises by at least 35 to 50% above baseline within 15 to 30 minutes. Blunted ACTH response with a preserved cortisol response to cosyntropin points to pituitary origin; blunted ACTH and blunted cortisol responses point to adrenal origin. This test is particularly useful in distinguishing secondary from tertiary adrenal insufficiency.

Medications That Directly Alter ACTH Levels

A number of drugs used in hormone-therapy and peptide protocols affect ACTH and must be accounted for during rate-of-change interpretation.

Exogenous Glucocorticoids

Any exogenous glucocorticoid suppresses CRH and ACTH through negative feedback. This includes oral prednisone, methylprednisolone, dexamethasone (which is 25 to 40 times more potent than cortisol on a milligram basis), topical betamethasone under occlusion, and high-dose inhaled fluticasone. Suppression begins within 24 to 48 hours of starting therapy. Dexamethasone does not cross-react with most cortisol immunoassays, making it the preferred agent when separating drug from endogenous cortisol signal.

Peptides and Secretagogues

Ipamorelin, sermorelin, and other growth hormone secretagogues do not directly stimulate ACTH secretion but can modestly increase cortisol through indirect mechanisms. CJC-1295 with DAC has been associated with mild morning cortisol increases in some users, which may suppress ACTH slightly on subsequent draws. Providers tracking ACTH trends in patients on GH peptide stacks should note the peptide timing in the medical record alongside each lab draw.

Metyrapone and Ketoconazole

These adrenal steroidogenesis inhibitors, used in Cushing syndrome management, block cortisol synthesis and drive compensatory ACTH elevation. Metyrapone at 750 mg every 4 hours can raise ACTH 5 to 10 times above baseline within 48 hours, which is actually the basis of the metyrapone stimulation test for pituitary reserve.

Interpreting ACTH in the Context of Hormonal Optimization Protocols

Patients on testosterone replacement therapy (TRT), thyroid hormone, or DHEA supplementation may show modest changes in baseline ACTH and cortisol.

Supraphysiologic testosterone has been shown to attenuate HPA axis reactivity in some studies. A trial published in Psychoneuroendocrinology (Hermans et al., 2010, N=36) found that a single dose of 500 mg testosterone cypionate reduced ACTH response to a social stress approach by approximately 25% compared to placebo (P<0.05) in healthy young men. [12]

DHEA (dehydroepiandrosterone) supplementation at 25 to 50 mg per day, commonly used in adrenal support protocols, provides an androgen substrate without significantly suppressing ACTH. However, very high-dose DHEA (>100 mg/day) may blunt adrenal ACTH responsiveness by providing peripheral androgen feedback.

Thyroid hormone (levothyroxine or T3 combinations) at standard replacement doses does not materially alter ACTH or cortisol. Hypothyroidism, on the other hand, can artifactually slow cortisol clearance and raise morning cortisol, which may suppress ACTH into the lower-normal range before thyroid replacement is optimized.

Clinical Decision Framework for ACTH Rate-of-Change Findings

The table below summarizes the four most common rate-of-change patterns encountered in clinical practice and the recommended next steps.

| Pattern | ACTH Trend | Cortisol Trend | Most Likely Explanation | Next Step | |---|---|---|---|---| | Pattern A | Rising (>50% over 8 wk) | Declining or flat | Primary adrenal insufficiency (early) | 250 mcg cosyntropin stimulation; adrenal antibody panel | | Pattern B | Declining (>50% over 8 wk) | Declining or flat | Secondary insufficiency or occult glucocorticoid exposure | Medication review; low-dose (1 mcg) cosyntropin; pituitary MRI | | Pattern C | Rising moderately (25 to 50% over 8 wk) | Rising proportionally | Physiological stress response or recovery from illness | Repeat draw after stress resolution; no intervention | | Pattern D | Stable within range | Declining only | Adrenal autonomy (subclinical Cushing or early autonomous cortisol secretion) | 1 mg overnight dexamethasone suppression test; adrenal imaging |

Special Populations and Considerations

Post-Adrenalectomy Patients

Bilateral adrenalectomy for refractory Cushing disease removes the cortisol source entirely, causing ACTH to rise to extremely high levels (often >1,000 pg/mL) if exogenous glucocorticoid replacement is insufficient. Nelson syndrome refers to the development of an aggressive ACTH-secreting pituitary adenoma in this setting, driven by loss of cortisol negative feedback. Annual ACTH trending is mandatory after bilateral adrenalectomy, with any progressive rise over 3 to 6 months prompting pituitary MRI.

Patients With Cushing Syndrome

In ACTH-dependent Cushing syndrome (pituitary Cushing disease or ectopic ACTH), plasma ACTH is elevated alongside cortisol. Distinguishing pituitary from ectopic source uses inferior petrosal sinus sampling (IPSS): a central-to-peripheral ACTH gradient of >2:1 at baseline or >3:1 after CRH confirms pituitary origin with approximately 95% sensitivity and specificity per the 2021 Endocrine Society Cushing syndrome guideline. [13]

Patients on GLP-1 Receptor Agonists

Semaglutide and tirzepatide are now used at scale for weight loss. GLP-1 receptors are expressed in the hypothalamus, and early animal data raised questions about HPA axis modulation. Current clinical evidence does not show clinically meaningful ACTH changes attributable to GLP-1 receptor agonists at approved doses in human trials. The STEP-1 trial (N=1,961) did not report adrenal adverse events above background rate with semaglutide 2.4 mg weekly over 68 weeks. [14]